Gene · 9846
Papers1,533
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 1,533
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multifaceted Regulation of Akt by Diverse C-Terminal Post-translational Modifications. | ACS Chem Biol | 2022 | 34941261 | PubTator, text mining | PubMed |
| Determination of tipping point in course of PM2.5 organic extracts-induced malignant transformation by dynamic network biomarkers. | J Hazard Mater | 2022 | 34933256 | PubTator, text mining | PubMed |
| Downregulation of METTL6 mitigates cell progression, migration, invasion and adhesion in hepatocellular carcinoma by inhibiting cell adhesion molecules. | Int J Oncol | 2022 | 34913069 | PubTator, text mining | PubMed |
| Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo. | Leukemia | 2022 | 34903841 | PubTator, text mining | PubMed |
| Role of microRNA‑218‑5p in sevoflurane‑induced protective effects in hepatic ischemia/reperfusion injury mice by regulating GAB2/PI3K/AKT pathway. | Mol Med Rep | 2022 | 34726254 | PubTator, text mining | PubMed |
| Kupffer cells regulate liver recovery through induction of chemokine receptor CXCR2 on hepatocytes after acetaminophen overdose in mice. | Arch Toxicol | 2022 | 34724096 | PubTator, text mining | PubMed |
| The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance. | Exp Dermatol | 2022 | 34717019 | PubTator, text mining | PubMed |
| DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma. | Oncogene | 2022 | 34675407 | PubTator, text mining | PubMed |
| Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. | Platelets | 2022 | 34097573 | PubTator, text mining | PubMed |
| Cushing syndrome and glucocorticoids: T-cell lymphopenia, apoptosis, and rescue by IL-21. | J Allergy Clin Immunol | 2022 | 34089750 | PubTator, text mining | PubMed |
| Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States-Based Subtyping in Bladder Cancer. | Front Cell Dev Biol | 2021 | 35223867 | PubTator, text mining | PubMed |
| Near-Haploidy and Low-Hypodiploidy in B-Cell Acute Lymphoblastic Leukemia: When Less Is Too Much. | Cancers (Basel) | 2021 | 35008193 | PubTator, text mining | PubMed |
| Transcriptome Analysis Reveals the Anti-cancerous Mechanism of Licochalcone A on Human Hepatoma Cell HepG2. | Front Nutr | 2021 | 34988109 | PubTator, text mining | PubMed |
| Disc Large Homolog 1 Is Critical for Early T Cell Receptor Micro Cluster Formation and Activation in Human T Cells. | Vaccines (Basel) | 2021 | 34960191 | PubTator, text mining | PubMed |
Integrated Gene Expression Profiling Analysis Reveals Potential Molecular Mechanisms and Candidate Biomarkers for Early Risk Stratification and Prediction of STEMI and Post-STEMI Heart Failure Patients. | Front Cardiovasc Med | 2021 | 34957234 | PubTator, text mining | PubMed |
| Experimental Characterization of the Interaction between the N-Terminal SH3 Domain of Crkl and C3G. | Int J Mol Sci | 2021 | 34947971 | PubTator, text mining | PubMed |
| Emerging Therapeutic Agents for Colorectal Cancer. | Molecules | 2021 | 34946546 | PubTator, text mining | PubMed |
| Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML. | Mol Ther Oncolytics | 2021 | 34938856 | PubTator, text mining | PubMed |
| Chronic myeloid leukemia stem cells: targeting therapeutic implications. | Stem Cell Res Ther | 2021 | 34922630 | PubTator, text mining | PubMed |
| Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA-minus RNA sequencing data. | Gigascience | 2021 | 34891161 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9846/papers?page=16